Data is available in a public repository; DOI [10.17605/OSF.IO/KPHRD](https://doi.org/10.17605/OSF.IO/KPHRD).

Background {#sec005}
==========

The crisis of antimicrobial resistance is already here with us, affecting both humans and animals alike and very soon, small cuts and surgeries will become life threatening. Evidence of non-prescribed use of antimicrobials in livestock to mask ill farming practices and misuse of antibiotics in community pharmacies has been documented globally \[[@pone.0231852.ref001], [@pone.0231852.ref002]\]. Farmers use large amounts of antibiotics in livestock and this is now known as a key driver and recipe to accelerating emergency of antimicrobial resistance \[[@pone.0231852.ref003]\]. Resistant bacterial clones may spread from animals to humans rendering antibiotics less effective and increases mortality and morbidity in developing nations due to such bacteria \[[@pone.0231852.ref003]\]. Previous studies in Uganda report abuse of antimicrobials in animal husbandry as a major contributor to antimicrobial resistance emergence among microbes. Additionally, 40% of the persons who visit a health- care facility in Uganda are treated with antibiotics \[[@pone.0231852.ref004]\]. These antibiotics are mostly obtained without prescription in drug shops and community pharmacies in sub-therapeutic doses. Globalization of trade coupled with the revolutionalization of travel has simplified distribution of resistant bacteria due to easy movement of humans and their goods including livestock across countries making the problem of antimicrobial resistance (AMR) global in nature.

The global spread of multi-drug resistant Enterobacteriaceae especially CTX-M type ESBLs and strains producing carbapenemases such as KPC and NDM warrant a multi-stake holder attention \[[@pone.0231852.ref005]\]. Resistance against certain antibiotic categories is already high in hospital settings in Uganda but resistance among bacteria from animals is not well documented. Introduction of bacteria with resistant genes into food animals as a result of antibiotic selection in veterinary medicine is now of great concern. Due to the routine consumption of certain antibiotics like tetracyclines in animal husbandry, undesirable shift of resistance towards potent second line and third generation antibiotics is now a reality \[[@pone.0231852.ref006], [@pone.0231852.ref007]\]. Baseline knowledge on the epidemiology and transmission routes of drug resistant microbes in Uganda is needed to drive the necessary prevention, intervention and control measures. While studies have been conducted in health care facilities in mostly urban areas settings \[[@pone.0231852.ref008], [@pone.0231852.ref009]\]. Little effort has been devoted to determining the molecular epidemiology of antimicrobial resistance, including multidrug resistance at a human-animal interface. Pastoralist communities live with their domestic animals inside the park hence a porous interface for microbial and disease transmission which provides a good ground for this study. We aimed to determine the whole genome sequences of multi-drug resistant *Escherichia coli* isolated in a Pastoralist Community of Western Uganda: phylogenomic changes, virulence and resistant genes.

Methods {#sec006}
=======

Bacterial strains {#sec007}
-----------------

Bacterial isolates analyzed in this study were multidrug resistant bacteria isolated from stool samples from both humans (n = 30) and cattle (n = 12) in pastoralist communities of Kasese district between January 2018-March 2019. The cattle were sample because they were the most common animals reared by the pastoralists in Kasese district. The pastoralist communities in Kasese district are settled in and around Queen Elizabeth National Park (QENP). The Kasese side of the National Park has two pastoralist communities in Nyakatonzi and Hima sub-countries. The QEPA lies astride the equator along the latitudes of 0Ê 39\' 36\" North, 30Ê 16\' 30\" East. The northern area has been occupied by pastoralists since the 1920s. Specific sites where samples were taken were Bwera-Mpondwe (Bwera) in the east, Hima in the north and Katwe-Kabatoro (Katwe).

Speciation and antibiotic susceptibility testing {#sec008}
------------------------------------------------

Speciation and antibiotic susceptibility of the isolates was done using the Phoenix automated microbiology system (Phoenix 100 ID/DST system) from Becton and Dickson (Franklin Lakes, NJ, USA) and the results interpreted using the CLSI guidelines. Sensitivity testing was carried out using a total of 15 antibiotics which include; ampicillin, amoxicillin-clavulanic acid, cefazolin, cefuroxime, ceftazidime, ceftriaxone, cefepime, ciprofloxacin, levofloxacin, gentamycin, tetracycline, nitrofurantoin, imipenem, Ertapenem and cotrimoxazole. Multi-drug resistance was defined as one isolate being resistant to three or more classes of antibiotics tested \[[@pone.0231852.ref010]\].

Extraction of Genomic bacterial DNA {#sec009}
-----------------------------------

Extraction of Genomic bacterial DNA was done at Molecular Biology Laboratory of Department of Immunology and Molecular Biology of Makerere University using Modified Cetyltrimethylammonium bromide (CTAB) Method as described before \[[@pone.0231852.ref011]\]. The modified CTAB method uses Enzymes and detergents to lyse cells, release the nucleic acids, and an organic solvent to purify the DNA and absolute alcohol (isopropanol/ethanol) to precipitate out the DNA.

Whole genome-sequencing {#sec010}
-----------------------

Whole Genome Sequencing (WGS) was carried out at the facilities of KEMRI Wellcome Trust Research Programme for the isolates that turned out to be multidrug resistant from house contacts and cattle. Genomic DNA from cultured *E*. *coli* was quantified using Qubit and diluted to 0.2ng/μl and library prep performed using the Illumina Nextera XT protocol according to the manufactures instructions. Briefly, gDNA was fragment and tagged with adapter sequences using a transposase enzyme in a process known as tagmentation. Using a limited cycle PCR step, indices were introduced. This helped in demultiplexing after sequencing was complete. A size selection clean-up was done using AMPure beads (AGENCOURT) and normalized to ensure equal representation of all libraries. The normalized libraries were pooled, denatured and loaded on the Miseq platform with an out of 2X200bp \[[@pone.0231852.ref012]\].

Bioinformatics analysis {#sec011}
-----------------------

Paired-end reads from each *E*. *coli* isolate were assembled de novo using spades v 3.11.1 algorithm \[[@pone.0231852.ref013]\] to generate a draft genome sequence for each isolate and quality assessment of for assemblies was done using QUAST 4.5. Clermont typing method \[[@pone.0231852.ref014], [@pone.0231852.ref015]\] was used to determine phylogroups basing on the genome-clustering tool called Mash \[[@pone.0231852.ref016]\].

Sequences were analysed using the Nullarbor pipeline (Seeman T, available at: <https://github.com/tseemann/nullarbor>). In brief, reads were trimmed to remove adaptor sequences and low-quality bases with Trimmomatic, \[[@pone.0231852.ref017]\] and Kraken (v1.1.1) was used to investigate for contamination \[[@pone.0231852.ref018]\]. Reads were aligned to the *E*. *coli* str. K-12 substr. MG1655 complete genome using the Burrows-Wheeler Aligner MEM (0.7.17-r1188) algorithm \[[@pone.0231852.ref019]\]. Samples with at least 21x depth of coverage and 76% genome coverage were retained for analysis. SNPs were identified using Freebayes (v1.3.1) with a minimum depth of coverage of 10x and allelic frequency of 0.9 required to confidently call a single nucleotide polymorphism (SNP) \[[@pone.0231852.ref020]\]. For all isolates, sequence reads covered \>76% of the reference genome, A total of 29,525 core SNP sites were identified, with 2,733 genes identified as core genes (present in \>99% of isolates).De novo assemblies were also performed using SPAdes (v. 3.13.1), \[[@pone.0231852.ref013]\] as part of the Nullarbor pipeline, with genes annotated using Prokka (v. 1.14.0, Seemann T, available at: <https://github.com/tseemann/prokka>).

*E*. *coli* has been traditionally clustered by phylogroup and have a good association with isolates being a commensal or pathogen \[[@pone.0231852.ref021]\]. The phylotyping method described by Clermont et al. (2013) \[[@pone.0231852.ref021]\] was performed *in silico*. In short, based on the presence or absence of 5 genes: *chuA*, *yjaA*, *tspE4*.*C2*, *arpA and trpA*, isolates can be separated into 8 phylogroups (A, B1, B2, D, C, E, F, and cryptic clades).

Each draft genome was screened for the presence of AMR and virulence genes using the software package Abricate (<https://github.com/tseemann/abricate>), a package for mass screening of contigs for antimicrobial resistance or virulence genes using databases. For antimicrobial resistance screening we used the [NCBI Bacterial Antimicrobial Resistance Reference Gene Database](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047) (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047>) and for virulence genes screening VFDB, a reference database for bacterial virulence factors \[[@pone.0231852.ref023]\]. Statistical analysis and visualisation were performed in R version 3.6.1 ([www.r-project.org](http://www.r-project.org/)).

Ethical considerations {#sec012}
----------------------

The study was approved by the Makerere University School of Biomedical Sciences Higher Degrees and Ethics Committee (SBS-HDREC) and The Uganda National Council of Science and Technology (UNCST). Written informed consent was obtained from all participants. All participant identifying information was kept confidential. Written informed consent from parents/guardians of participants below 18 years was sought and written assent was provided by all minors who were able to read and write who voluntarily participated in this study while those who were not able to read and write provided verbal assent. Verbal assent was witnessed by the parent/guardian.

Results {#sec013}
=======

Antibiotic susceptibility pattern {#sec014}
---------------------------------

Antibiotic susceptibility testing was carried out on all the 42 *E*. *coli* isolated from both human and animals. A majority of the isolates displayed high resistance to ampicillin, cefazolin, trimethoprim/sulphurmethoxazole, amoxicillin/clavulanic acid and Cefotaxime. Low resistance to imipenem, ciprofloxacin, Levofloxacin Ertapenem were recorded whereas only one isolate was resistant to gentamicin. Most of the isolates 41/42 were resistant to three or more antibiotics (multi-drug resistant) and 21/42 isolates were ESBL producers.

Whole genome sequencing and de novo assembly {#sec015}
--------------------------------------------

Computation of the total number of reads and quality metrics of the showed homogenous results with a good quality profile for all isolates assemblies. Estimated average depth of coverage for 42 *E*. *coli* isolates on which WGS was performed was 28× with an average of 197 contigs \>500-base pairs after genome assembly using SPAdes.

Phylogenetic analysis of the *E*. *coli* Isolated from humans and cattle {#sec016}
------------------------------------------------------------------------

The genomes of *E*. *coli* from humans and animals were clustered according to single nucleotide polymorphism in core genes. At household level, the genomes from both human and animals clustered away from one another except for one instance where two human isolates from the same household clustered together. However, 67% of the *E*. *coli* isolated from cattle were closely related to those found in humans ([Fig 1](#pone.0231852.g001){ref-type="fig"}). All the four major *E*. *coli* phylotypes were identified through *in silico* phylotyping. Most isolates belonged to phylotype B1, which accounted for 38% (n = 16) of *E*. *coli* isolates, evenly split between human and cattle samples ([Fig 1](#pone.0231852.g001){ref-type="fig"}). Phylotypes A and D accounted for 31% (n = 13) and 9.5% (n = 4) of isolates respectively, with the majority of the phylogroup A isolated from human samples and only two from cattle. The majority of isolates from Hima location are phylotype B1 and A.

![Maximum likelihood phylogenetic trees based on SNP differences within the core genomes and antibiotic susceptibility of *E*. *coli* isolated from humans and animals in Kasese district.\
The black shading indicates resistance. ESBL = Extended Spectrum β-lactamase, AMP = ampicillin, AMC = amoxicillin/clavulanic acid, FAS = cefazolin, CTX = Cefotaxime, CAZ = ceftazidime, CRO = ceftriaxone, FEP = cefepime, ERT = ertapenem, IMP = imipenem, CN = gentamicin CIP = ciprofloxacin, LEV = levofloxacin, TET = tetracycline, NIT = nitrofurantoin, SXT = trimethoprim/sulphurmethoxazole.](pone.0231852.g001){#pone.0231852.g001}

Antibiotic susceptibility pattern {#sec017}
---------------------------------

Antibiotic susceptibility testing was carried out on all the 42 *E*. *coli* isolated from both human and cattle. Generally, a majority of the isolates displayed high resistance to cefazolin (100%), ampicillin (98%), Cefotaxime (67%), trimethoprim/sulphurmethoxazole (64%) and amoxicillin/clavulanic acid (62%). Low resistance to ciprofloxacin (5%), imipenem (10%), and Levofloxacin (12%) were recorded whereas only one isolate was resistant to gentamicin (2%). Most of the isolates 41/42 were resistant to three or more antibiotics (multi-drug resistant) and 21/42 isolates were ESBL producers ([Fig 1](#pone.0231852.g001){ref-type="fig"}). All the isolates assigned to phylogroup A were resistant to ampicillin, cefazolin and trimethoprim/sulfamethoxazole but sensitive to imipenem, gentamicin, ciprofloxacin, levofloxacin and tetracycline. All phylogroup B1 isolates were resistant to cefazolin but sensitive to imipenem, gentamicin and tetracycline. There was also high resistance against ampicillin (94%), amoxicillin/clavulanic acid (94%).

Generally, there was a similar pattern of antibiotic resistance among the *E*. *coli* isolated from human and that isolated from cattle with the trends in cattle appearing higher than those in humans ([Fig 2](#pone.0231852.g002){ref-type="fig"}). All the isolates from cattle and humans were resistant to cefazolin. All the human isolates were resistant to ampicillin and highly resistant to trimethoprim/sulfamethoxazole 21(70%), amoxicillin/clavulanic acid, 20(67%) and Cefotaxime, 19(63%). Low resistance against gentamicin 1(3%), ciprofloxacin, 2(7%) and imipenem, 3(10%) was detected among the isolates from humans. The isolates from cattle were highly resistant to ampicillin, 11(91%) and Cefotaxime, 9(75%) and no resistance was detected against gentamicin, ciprofloxacin and levofloxacin. There was no significant difference in resistance to particular drugs between the human and cattle isolates except for Cotrimoxazole (p\<0.05).

![Phenotypic antibiotic resistance patterns in humans and cattle.\
ESBL = Extended Spectrum β-lactamase, AMP = ampicillin, AMC = amoxicillin/clavulanic acid, FAS = cefazolin, CTX = Cefotaxime, CAZ = ceftazidime, CRO = ceftriaxone, FEP = cefepime, ERT = ertapenem, IMP = imipenem, CN = gentamicin CIP = ciprofloxacin, LEV = levofloxacin, TET = tetracycline, NIT = nitrofurantoin, SXT = trimethoprim/sulphurmethoxazole.](pone.0231852.g002){#pone.0231852.g002}

Comparison of virulence genes identified in *E*. *coli* genomes, isolated and sequenced from human and cattle samples {#sec018}
---------------------------------------------------------------------------------------------------------------------

Antimicrobial resistance genes were identified in all 30 *E*. *coli* genomes from human and the 12 *E*. *coli* genomes from cattle. The carriage of virulence genes was significantly higher among the *E*. *coli* isolates from humans compared to those of cattle origin ([Fig 3](#pone.0231852.g003){ref-type="fig"}) and this rule out the possibility of clonal relationship between the isolates from the two hosts (p = 0.18). Isolates from Katwe location had significantly higher number of virulence genes compared to the other two sites, Bwera and Hima (p = 0.04). The human samples have a significantly higher number of virulence genes compared to bovine samples. However, there was no difference in the median of the virulence genes from the *E*. *coli* isolated from the hospital and that isolated from the community ([Fig 4](#pone.0231852.g004){ref-type="fig"}).

![Box plots showing the median values for the number of virulence genes in the two groups along with the interquartile range.\
The human samples had a significantly higher number of virulence genes compared to bovine samples. The *E*. *coli* strains from Katwe had significantly higher number of virulence genes compared to Bwera and Hima.](pone.0231852.g003){#pone.0231852.g003}

![Box plots comparing the variation in virulence of the *E*. *coli* from hospital and the community.\
Homestead = community isolated *E*. *coli*, species = human/cattle.](pone.0231852.g004){#pone.0231852.g004}

Detection of virulence factors genes {#sec019}
------------------------------------

A total of 174 different virulence genes were detected from the *E*. *coli* genomes. The virulence genes; cheY, csgG, entC, entF, entS, fepB, fepC, fepD and flgG were detected in all the *E*. *coli* isolates. Other virulent genes that were commonly prevalent include; csgB, csgD, csgE, entA, entB, fdaC, fimA, fim B, fimC, fimD, fimE, fimF, fimG, fimH, fimI, flgG, flhA, fliG, fliM, flip, gspC, gspD, gspE, gspF, gspG, gspH, gspI, gspJ, gspK, gspL, gspM, ompA, yagV/ecpE, yagW/ecpD, yagX/ecpC, yagY/ecpB, yagZ/ecpA and ykgk/ecpB. The proportion of virulence genes from the two hosts was analyzed and presented in box plots ([Fig 3](#pone.0231852.g003){ref-type="fig"}).

Discussion {#sec020}
==========

Whole genome sequencing was used to analyse non--duplicate *E*. *coli* isolated from both human and cattle in pastoralist communities of Kasese district. Phylogenetic analysis showed that the genomes of the human *E*. *coli* generally clustered together and away from those of cattle origin and likewise the genomes from cattle tended to cluster together and away from those of the cattle origin. The human isolates were mainly assigned to phylogroup A and B1 whereas the cattle isolates were mostly assigned to phylogroup B1. This finding agrees with the Zambian study which reported that most of the cattle isolates of E. coli were assigned to phylogroup B1 which is commonly associated with commensal existence \[[@pone.0231852.ref024]\]. Phylogroups B2, Clade l, E and F; were associated with only the *E*. *coli* isolated from humans, three human isolates were assigned to phylogroup D and only one cattle isolate was assigned to group D. The presence of phylogroups B2 and D among human isolates presents a risk for infection due to *E*. *coli* in humans. Phylogroups B2 and D have been reported to be pathogenic and responsible for extra-intestinal infections by a number of studies \[[@pone.0231852.ref025]--[@pone.0231852.ref028]\].

Phenotypic resistance testing revealed a similar resistance pattern among the human isolates than the cattle isolates for the 15 antibiotics tested in this study. A similar study in Lusaka-Zambia demonstrated significantly higher levels of resistance among the human *E*. *coli* isolates when the same antibiotics were tested \[[@pone.0231852.ref024]\]. Every year, humans produce, use, and consume approximately 175,000 tons of antibiotics \[[@pone.0231852.ref029]\] which makes emergency of AMR in humans, animals and environment inevitable. The resistance genes were also compared in *E*. *coli* isolates originating from the two hosts. The carriage of multiple AMR genes among the *E*. *coli* population from humans was higher than those from cattle ([Fig 5](#pone.0231852.g005){ref-type="fig"}). There have been several debates trying to link the emergency of AMR in humans to antibiotic use in food animals \[[@pone.0231852.ref030]--[@pone.0231852.ref032]\]. Our study, like the study in Zambia \[[@pone.0231852.ref024]\], showed that there was much more diversity in the resistance genotypes present in human isolates than in the cattle isolates. The deference in the diversity of the resistance genotype could indicate the existence of independent AMR selection pressures in human and animals. Whereas other studies have demonstrated the predominance of blaCTX-M-15 allele among human and animal isolates of *E*. *coli*, from the community \[[@pone.0231852.ref033], [@pone.0231852.ref034]\], this study identified arsB-mob (80%) as the most predominant allele ([Fig 2](#pone.0231852.g002){ref-type="fig"}). This discrepancy could be due to the different methods used and undetermined geographical factors. Another study in livestock in Uganda indicated that blaCTX-M and carbapenems resistant genes were not harboured by *E*. *coli* from livestock \[[@pone.0231852.ref035]\]. The prevalence of cephalosporin resistance genes in the *E*. *coli* isolated from cattle in this study presents a risk of transmission of these resistant genes from animals to humans. Similar observations have been made by Okubo et al., in Uganda \[[@pone.0231852.ref035]\]. In this study, the prevalence of resistance genes was high both in human and cattle isolates.

![Heat map showing AMR genes found in the genomes of sequenced *E*. *coli* isolates.\
AMR genes are annotated with the [NCBI Bacterial Antimicrobial Resistance Reference Gene Database](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047) with \>95% coverage. The names of the strains indicated on the y axis are presented in the same order as in [Fig 2](#pone.0231852.g002){ref-type="fig"}. aadA1, aadAd2, aadAD5: Streptomycin 3\'\'-adenylyltransferase; aph(3\'\')-Ib, aph(6)-Id: Streptomycin phosphotransferase; arsB-mob: Arylsulfatase B; blaEC, blaEC-13, blaEC-15, blaEC-18, blaEC-19, blaEC-5, blaEC-8: Beta-lactamase; blaOXA-1: Class D beta-lactamases; blaTEM-1, blaTEM-235: Beta-lactamase; catA1: chloramphenicol acetyl transferase; cmlA1: chloramphenicol efflux transporter; dfrA1, dfrA12, dfrA14, dfrA15, dfrA17, dfrA5, dfrA7, dfrA8: [trimethoprim resistant dihydrofolate reductase](https://card.mcmaster.ca/ontology/37617); fosA: [fosfomycin thiol transferase](https://card.mcmaster.ca/ontology/36272); mph(A): [macrolide phosphotransferase](https://card.mcmaster.ca/ontology/36472); oqxB11: RND efflux pump conferring resistance to fluoroquinolone; qacL, qacEdelta1: Small multidrug resistance gene; qepA4: quinolone efflux pump; qnrS1: quinolone resistance gene; sul1, sul2, sul3: sulfonamide resistant; tet(A), tet(B): tetracycline efflux pump (Fig 5).](pone.0231852.g005){#pone.0231852.g005}

A high variation of virulence genes was registered among the *E*. *coli* genome from humans than those of cattle origin further supports the hypothesis that the *E*. *coli* isolated from the two hosts have a common ancestral origin. However, some studies have found clonal commonality between *E*.*coli* isolated from the hospital, the community and animals \[[@pone.0231852.ref036]\]. The reason for this discrepancy is mainly due to the different methods used. Also, there was no difference in median of virulence genes between the *E*. *coli* isolated from hospital from that isolated from the community and this may imply that the *E*. *coli* isolated from the two hosts have similar evolutionary pressures.

Conclusions {#sec021}
===========

From the analysis of the core genome and phenotypic resistance, this study has demonstrated that the *E*. *coli* of human origin and those of cattle origin may have a common ancestry. Limited sharing of virulence genes presents a challenge to the notion that AMR in humans is as a result of antibiotic use in the farm and distorts the picture of the directionality of transmission of AMR at a human-animal interface and presents a task of exploring alternative routes of transmission of AMR. A major limitation of this study is the small number of isolates sequenced and only one species of animals studied, therefore, we recommend a larger study for better generalization of results.

We gratefully acknowledge our participants for making this study possible. Heartfelt thanks to Stallone Kisembo and Zaydah De Laurent for the great work they did as research assistants.
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Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The study provided by Authors gives an overview on genetic profile of collected strains (n=42) from cattle and human in Kasese District, Uganda. The Authors concluded that major results stays contrary to thesis that antimicrobial resistance (AMR) may be passed to human from livestock as a result of antibiotic use in the farm.

Methods provided by Authors are sound and well based. However discussion section and conclusion should be revised, please find following remarks below:

A\) Major remarks:

1\. Please highlight the exact number of tested strains in abstract. Cattle (n=12) and human (n=30). In abstract we can found: \[...\] 21/42 isolates were ESBL producers; 13/42 from human and 8/42 from cattle -- it remains unclear, and suggest there were 84 samples. I suggest to use 13/30 and 8/12 instead, respectively.

2\. Please indicate the exact number of tested strains in Methods section, subsection Bacterial strains as mentioned above

3\. Major conclusion made by Authors stays a little bit contrary to data provided in Figure 2. According to Figure 2 about 8 cattle E. coli strains (60% of all cattle samples) are closely related to this found in human and the several of them have similar or wider pattern of AMR.

4\. Could you explain why only cattle was designated to the study? If the cattle is the most important meat donor in Uganda, such thing should be mentioned in the background section.

5\. Consider discuss other work i.e work of Okubo et al (1) in meaning possibility of obtaining AMR genes from other livestock

6\. Because of relative small number of samples in case of cattle (n=12), and no comparison to other livestock (lack of discussion i.e abovementioned) the conclusion may be misleading.

B\) Minor remarks:

1\. consider the necessity of Figure 1. It is not essential for study.

\- Please correct:

2\. Method section: Whole genome-sequencing: "Briefly, gDNA was fragmented and

tagged with \[...\]"

3\. Figure 2: last strain: Catt-BWE_048B -- should be probably Bovine not Human in Host section.

4\. I suggest to revise paper by native English speaker.

In conclusion, the study provided by authors are interesting and presents valuable data. I recommend to publish it after revision.

1\. Okubo T, Yossapol M, Maruyama F, Wampande EM, Kakooza S, Ohya K, et al. Phenotypic and genotypic analyses of antimicrobial resistant bacteria in livestock in Uganda. Transbound Emerg Dis \[Internet\]. 2019 Jan 22;66(1):317--26. Available from: <https://doi.org/10.1111/tbed.13024>

Reviewer \#2: The article prepare by the authors present a serious problem which is E. coli multi-drug resistance. It is very interesting that it was observed similar pattern of antibiotic resistance both in human and cattle. Paper is written correctly, the Figures are very impressing, however there are small details which should be corrected.

In Manuscript draft there are missing keywords, however there are present in main document so I assumed that this is omission. In some places like in page 5 Escherichia coli is not written in italic. When you once use shortcut \"E. coli\" in the text do not use full name in further part. You should write \"ng/µl\" not \"ng/ul\" (page 4).

In Results I thought that it will be more genetic data, knowing the title of article. That part could be improved. In addition despite the fact that the Discussion is written correctly and in scientific way, it also could be improved. For a research article the Discussion is to short, try write more about importance of your results regarding to other papers.

Summary, the article is very interesting and the data are important equally for human health and agriculture. I recommend this paper for publication after minor revision.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0231852.r002
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Response to Reviewers

Editor's comments

SN COMMENT AUTHOR'S RESPONSE

1 Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. This has been corrected as recommended

2 Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified how verbal consent was documented and witnessed. Additional details regarding participant consent and the ethical statement

3 We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. The data availability statement has been updated.

4 Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript The ethical statement has been relocated to the methods

5 Please ensure that you refer to Figure 5 in your text as, if accepted, production will need this reference to link the reader to the figure Figure 5 has been referenced in the text

6 Please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. The figure has been removed

Reviewer 1

SN COMMENT AUTHOR'S RESPONSE

1 Please highlight the exact number of tested strains in abstract. Cattle (n=12) and human (n=30). In abstract we can found: \[...\] 21/42 isolates were ESBL producers; 13/42 from human and 8/42 from cattle -- it remains unclear, and suggest there were 84 samples. I suggest to use 13/30 and 8/12 instead, respectively. The exact numbers tested have been highlighted as recommended by the reviewer. Thank you

2 Please indicate the exact number of tested strains in Methods section, subsection Bacterial strains as mentioned above Amended as recommended by the reviewer

3 Major conclusion made by Authors stays a little bit contrary to data provided in Figure 2. According to Figure 2 about 8 cattle E. coli strains (60% of all cattle samples) are closely related to this found in human and the several of them have similar or wider pattern of AMR. The conclusion has been amended as to reflect the results.

4 Could you explain why only cattle was designated to the study? If the cattle is the most important meat donor in Uganda, such thing should be mentioned in the background section. The pastoralists in Kasese district majorly reared cattle. This has been mention in the manuscript

5 Consider discuss other work i.e work of Okubo et al (1) in meaning possibility of obtaining AMR genes from other livestock This has been used to enrich the discussion, thank you.

6 Because of relative small number of samples in case of cattle (n=12), and no comparison to other livestock (lack of discussion i.e abovementioned) the conclusion may be misleading. This has acknowledged as a limitation

7 consider the necessity of Figure 1. It is not essential for study. The figure has been deleted

8 Method section: Whole genome-sequencing: "Briefly, gDNA was fragmented and

tagged with \[...\]" The reference has been added

Reviewer 2

SN COMMENT AUTHOR'S RESPONSE

1 In Manuscript draft there are missing keywords, however there are present in main document so I assumed that this is omission. In some places like in page 5 Escherichia coli is not written in italic. When you once use shortcut \"E. coli\" in the text do not use full name in further part. You should write \"ng/µl\" not \"ng/ul\" (page 4). Key words have been added and all other comments addressed as recommended by the reviewer

2 In Results I thought that it will be more genetic data, knowing the title of article. That part could be improved. In addition despite the fact that the Discussion is written correctly and in scientific way, it also could be improved. For a research article the Discussion is to short, try write more about importance of your results regarding to other papers. Some adjustments have been made
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Click here for additional data file.
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Dear Dr. Iramiot,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Grzegorz Woźniakowski, PhD ScD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dear Author

Thank you for applying indicated remarks.

Please verify english by native speaker.

I\'ve got no further comments.

I recommend to publish manuscript after english verification.

Kind regards.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0231852.r004
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Dear Dr. Iramiot:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Grzegorz Woźniakowski

Academic Editor
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